Denali Therapeutics
Edit

Denali Therapeutics

http://www.denalitherapeutics.com/
Last activity: 03.09.2024
Active
Categories: DevelopmentDrugLearn
Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Website visits
23.8K /mo.
Mentions
36
Location: United States, California, South San Francisco
Employees: 201-500
Total raised: $347M
Founded date: 2015

Investors 6

Funding Rounds 2

DateSeriesAmountInvestors
28.08.2016Series B$130MARCH Ventu...
15.05.2015-$217M-

Mentions in press and media 36

DateTitleDescription
03.09.2024Parkinson’s Disease Drug Market: Trends, Growth, and SegmentationShare Tweet Share Share Email Parkinson’s disease, a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, affects millions of individuals worldwide. As the global population age...
15.03.2024HiLabs closes $39 million Series B financingHiLabs a leading provider of AI-powered solutions to clean dirty data, unlocking its hidden potential for healthcare transformation closed a $39 million Series B financing. The round was led by our Eight Roads Ventures India team and Denali...
27.02.2024Denali Therapeutics Announces $500 million Private Placement Equity Financing-
27.09.2022FDA slaps a par­tial hold on Avid­i­ty's mAb-siR­NA ther­a­py, paus­ing en­roll­ment in mus­cle weak­ness dis­ease studyAvid­i­ty Bio­sciences will have to wait to en­roll new pa­tients in a Phase I/II study of its ther­a­py for my­oton­ic dy­s­tro­phy type 1, or DM1, which weak­ens mus­cles and leads to res­pi­ra­to­ry and car­diac is­sues. The FDA is dock­...
10.01.2022Denali Therapeutics Announces Progression and Expansion of Broad Therapeutic Portfolio for Neurodegeneration and Expected Key Milestones in 2022Key data readouts to include additional Phase 1/2 data on DNL310 (ETV:IDS) in MPS II (Hunter syndrome) and the first clinical data on DNL919 (ATV:TREM2), both potentially further validating Denali’s Transport Vehicle (TV) platform; in addit...
10.01.2022Denali Therapeutics : Announces Progression and Expansion of Broad Therapeutic Portfolio for Neurodegeneration and Expected Key Milestones in 2022 - Form 8-KDenali Therapeutics Announces Progression and Expansion of Broad Therapeutic Portfolio for Neurodegeneration and Expected Key Milestones in 2022 •Key data readouts to include additional Phase 1/2 data on DNL310 (ETV:IDS) in MPS II (Hunter s...
06.10.2021Denali Therapeutics : Announces Positive Clinical Results and Regulatory Progress for Development Programs in Amyotrophic Lateral Sclerosis (ALS)eIF2B activator DNL343 achieved safety and biomarker goals in a Phase 1 study in healthy volunteers; a Phase 1b study began in individuals with ALS in Q3 2021 Fast Track designation granted by the U.S. Food and Drug Administration (FDA) to ...
29.09.2021Denali Therapeutics : Announces Upcoming Presentations on EIF2B Activator DNL343 and RIPK1 Inhibitor SAR443820/DNL788 at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) MeetingDenali to present results from Phase 1 healthy volunteer study of EIF2B activator DNL343 Sanofi to present Phase 2 study plans in ALS for RIPK1 inhibitor SAR443820 Denali to host analyst and investor webinar on October 6, at 4:30 p.m. Easte...
12.02.2021De­nali un­veil proof-of-con­cept da­ta for brain de­liv­ery tech in rare dis­ease, with eyes on much big­ger in­di­ca­tionsNear­ly a year af­ter un­veil­ing their brain de­liv­ery tech­nol­o­gy in Sci­ence Trans­la­tion­al Med­i­cine, De­nali has de­liv­ered promis­ing new re­sults from a tri­al that used it on pa­tients with a rare ge­net­ic dis­ease and could...
30.04.2019After amyloid failures, it’s time to take a new tack for treating Alzheimer’sIf insanity is doing the same thing over and over again but expecting different results, then the last decade or so of Alzheimer’s disease drug development has been insane. Three carefully designed, well-executed, and fully resourced trials...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In